Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: Update on recommendations from the British Association for Psychopharmacology
Attention deficit hyperactivity disorder (ADHD) is a common condition with a high societal burden. The present guidelines summarise current literature, generating expert consensus recommendations for the treatment of ADHD in children and adults. These guidelines also provide a review of recent resea...
Gespeichert in:
| Veröffentlicht in: | Journal of Psychopharmacology 2014-03, Vol.28 (3), p.179-203 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 203 |
|---|---|
| container_issue | 3 |
| container_start_page | 179 |
| container_title | Journal of Psychopharmacology |
| container_volume | 28 |
| creator | Bolea-Alamañac, Blanca Nutt, David J Adamou, Marios Asherson, Phillip Bazire, Stephen Coghill, David Heal, David Müller, Ulrich Nash, John Santosh, Paramala Sayal, Kapil Sonuga-Barke, Edmund Young, Susan J |
| description | Attention deficit hyperactivity disorder (ADHD) is a common condition with a high societal burden. The present guidelines summarise current literature, generating expert consensus recommendations for the treatment of ADHD in children and adults. These guidelines also provide a review of recent research in the fields of neuroimaging, neuropsychology and genetics of ADHD. Novel discoveries in these areas have informed physiological models for the disease. Since the publication of the previous British Association for Psychopharmacology guidelines in 2008, new drugs have been licensed and further compounds are being investigated. The publication of randomised controlled trials of psychological interventions has contributed to the range of treatment options for ADHD. As the disorder has been diagnosed more frequently there has been greater focus on comorbid conditions and how they impact treatment. Services have continued to develop for the treatment of ADHD in adults and care agreements have been introduced to facilitate access to treatment. |
| doi_str_mv | 10.1177/0269881113519509 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1516756086</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_0269881113519509</sage_id><sourcerecordid>3244085221</sourcerecordid><originalsourceid>FETCH-LOGICAL-c494t-4f10cc7e1cfb882fc5cf141ffa0370a925498a322e12b4ad1edbcec11813e7603</originalsourceid><addsrcrecordid>eNqNkU9v1DAQxSMEotvCnROyhJC4BDzxnyTc2qoFpEpwoOfIccYbV0m82E6lfDK-Hs7uAlUlJE72aH7z3oxelr0C-h6gLD_QQtZVBQBMQC1o_STbAJeQl0UlnmabtZ2v_ZPsNIQ7SkFyKZ5nJwUXhQTGN9nPq3vb4aQxb1XAjmznVA52wkCM8yT2SHa98qPSbnBbq9VARjWpLY44ReIMUTGmn3UT6dBYbSPplx16paO9t3EhnQ3Od-g_kttdpyKSRHrUbkwCqU6Dycm7cW914W20oSfnITht9939Gt_Conv3YJHlRfbMqCHgy-N7lt1eX32__JzffP305fL8Jte85jHnBqjWJYI2bVUVRgttgIMxirKSqroQvK4UKwqEouWqA-xajRqgAoalpOwse3fQ3Xn3Y8YQm9EGjcOgJnRzaECALIWklfwPlHIuasF4Qt88Qu_c7Kd0yEpJIQUrV0F6oLR3IXg0zc7bUfmlAdqs-TeP808jr4_Cczti92fgd-AJeHsEVEhhGq8mbcNfrkqKjK3e-YELKesH2_3L-BcRvcj2</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1506565376</pqid></control><display><type>article</type><title>Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: Update on recommendations from the British Association for Psychopharmacology</title><source>MEDLINE</source><source>SAGE Complete</source><creator>Bolea-Alamañac, Blanca ; Nutt, David J ; Adamou, Marios ; Asherson, Phillip ; Bazire, Stephen ; Coghill, David ; Heal, David ; Müller, Ulrich ; Nash, John ; Santosh, Paramala ; Sayal, Kapil ; Sonuga-Barke, Edmund ; Young, Susan J</creator><creatorcontrib>Bolea-Alamañac, Blanca ; Nutt, David J ; Adamou, Marios ; Asherson, Phillip ; Bazire, Stephen ; Coghill, David ; Heal, David ; Müller, Ulrich ; Nash, John ; Santosh, Paramala ; Sayal, Kapil ; Sonuga-Barke, Edmund ; Young, Susan J ; British Association for Psychopharmacology ; for the Consensus Group</creatorcontrib><description>Attention deficit hyperactivity disorder (ADHD) is a common condition with a high societal burden. The present guidelines summarise current literature, generating expert consensus recommendations for the treatment of ADHD in children and adults. These guidelines also provide a review of recent research in the fields of neuroimaging, neuropsychology and genetics of ADHD. Novel discoveries in these areas have informed physiological models for the disease. Since the publication of the previous British Association for Psychopharmacology guidelines in 2008, new drugs have been licensed and further compounds are being investigated. The publication of randomised controlled trials of psychological interventions has contributed to the range of treatment options for ADHD. As the disorder has been diagnosed more frequently there has been greater focus on comorbid conditions and how they impact treatment. Services have continued to develop for the treatment of ADHD in adults and care agreements have been introduced to facilitate access to treatment.</description><identifier>ISSN: 0269-8811</identifier><identifier>EISSN: 1461-7285</identifier><identifier>DOI: 10.1177/0269881113519509</identifier><identifier>PMID: 24526134</identifier><identifier>CODEN: JOPSEQ</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Adult ; Attention Deficit Disorder with Hyperactivity - drug therapy ; Attention Deficit Disorder with Hyperactivity - etiology ; Attention Deficit Disorder with Hyperactivity - psychology ; Attention deficit hyperactivity disorder ; Biological and medical sciences ; Central Nervous System Stimulants - therapeutic use ; Child ; Comorbidity ; Consensus ; Evidence-Based Medicine ; Humans ; Medical sciences ; Mental health care ; Nervous system (semeiology, syndromes) ; Nervous system as a whole ; Neurology ; Neuropharmacology ; Neuropsychology ; Pharmacology. Drug treatments ; Psychopharmacology</subject><ispartof>Journal of Psychopharmacology, 2014-03, Vol.28 (3), p.179-203</ispartof><rights>The Author(s) 2014</rights><rights>2015 INIST-CNRS</rights><rights>Copyright Sage Publications Ltd. Mar 2014</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c494t-4f10cc7e1cfb882fc5cf141ffa0370a925498a322e12b4ad1edbcec11813e7603</citedby><cites>FETCH-LOGICAL-c494t-4f10cc7e1cfb882fc5cf141ffa0370a925498a322e12b4ad1edbcec11813e7603</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/0269881113519509$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/0269881113519509$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>313,314,776,780,788,21798,27899,27901,27902,43597,43598</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=28269336$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24526134$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bolea-Alamañac, Blanca</creatorcontrib><creatorcontrib>Nutt, David J</creatorcontrib><creatorcontrib>Adamou, Marios</creatorcontrib><creatorcontrib>Asherson, Phillip</creatorcontrib><creatorcontrib>Bazire, Stephen</creatorcontrib><creatorcontrib>Coghill, David</creatorcontrib><creatorcontrib>Heal, David</creatorcontrib><creatorcontrib>Müller, Ulrich</creatorcontrib><creatorcontrib>Nash, John</creatorcontrib><creatorcontrib>Santosh, Paramala</creatorcontrib><creatorcontrib>Sayal, Kapil</creatorcontrib><creatorcontrib>Sonuga-Barke, Edmund</creatorcontrib><creatorcontrib>Young, Susan J</creatorcontrib><creatorcontrib>British Association for Psychopharmacology</creatorcontrib><creatorcontrib>for the Consensus Group</creatorcontrib><title>Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: Update on recommendations from the British Association for Psychopharmacology</title><title>Journal of Psychopharmacology</title><addtitle>J Psychopharmacol</addtitle><description>Attention deficit hyperactivity disorder (ADHD) is a common condition with a high societal burden. The present guidelines summarise current literature, generating expert consensus recommendations for the treatment of ADHD in children and adults. These guidelines also provide a review of recent research in the fields of neuroimaging, neuropsychology and genetics of ADHD. Novel discoveries in these areas have informed physiological models for the disease. Since the publication of the previous British Association for Psychopharmacology guidelines in 2008, new drugs have been licensed and further compounds are being investigated. The publication of randomised controlled trials of psychological interventions has contributed to the range of treatment options for ADHD. As the disorder has been diagnosed more frequently there has been greater focus on comorbid conditions and how they impact treatment. Services have continued to develop for the treatment of ADHD in adults and care agreements have been introduced to facilitate access to treatment.</description><subject>Adult</subject><subject>Attention Deficit Disorder with Hyperactivity - drug therapy</subject><subject>Attention Deficit Disorder with Hyperactivity - etiology</subject><subject>Attention Deficit Disorder with Hyperactivity - psychology</subject><subject>Attention deficit hyperactivity disorder</subject><subject>Biological and medical sciences</subject><subject>Central Nervous System Stimulants - therapeutic use</subject><subject>Child</subject><subject>Comorbidity</subject><subject>Consensus</subject><subject>Evidence-Based Medicine</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Mental health care</subject><subject>Nervous system (semeiology, syndromes)</subject><subject>Nervous system as a whole</subject><subject>Neurology</subject><subject>Neuropharmacology</subject><subject>Neuropsychology</subject><subject>Pharmacology. Drug treatments</subject><subject>Psychopharmacology</subject><issn>0269-8811</issn><issn>1461-7285</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkU9v1DAQxSMEotvCnROyhJC4BDzxnyTc2qoFpEpwoOfIccYbV0m82E6lfDK-Hs7uAlUlJE72aH7z3oxelr0C-h6gLD_QQtZVBQBMQC1o_STbAJeQl0UlnmabtZ2v_ZPsNIQ7SkFyKZ5nJwUXhQTGN9nPq3vb4aQxb1XAjmznVA52wkCM8yT2SHa98qPSbnBbq9VARjWpLY44ReIMUTGmn3UT6dBYbSPplx16paO9t3EhnQ3Od-g_kttdpyKSRHrUbkwCqU6Dycm7cW914W20oSfnITht9939Gt_Conv3YJHlRfbMqCHgy-N7lt1eX32__JzffP305fL8Jte85jHnBqjWJYI2bVUVRgttgIMxirKSqroQvK4UKwqEouWqA-xajRqgAoalpOwse3fQ3Xn3Y8YQm9EGjcOgJnRzaECALIWklfwPlHIuasF4Qt88Qu_c7Kd0yEpJIQUrV0F6oLR3IXg0zc7bUfmlAdqs-TeP808jr4_Cczti92fgd-AJeHsEVEhhGq8mbcNfrkqKjK3e-YELKesH2_3L-BcRvcj2</recordid><startdate>20140301</startdate><enddate>20140301</enddate><creator>Bolea-Alamañac, Blanca</creator><creator>Nutt, David J</creator><creator>Adamou, Marios</creator><creator>Asherson, Phillip</creator><creator>Bazire, Stephen</creator><creator>Coghill, David</creator><creator>Heal, David</creator><creator>Müller, Ulrich</creator><creator>Nash, John</creator><creator>Santosh, Paramala</creator><creator>Sayal, Kapil</creator><creator>Sonuga-Barke, Edmund</creator><creator>Young, Susan J</creator><general>SAGE Publications</general><general>Sage Publications</general><general>Sage Publications Ltd</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>7X8</scope></search><sort><creationdate>20140301</creationdate><title>Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: Update on recommendations from the British Association for Psychopharmacology</title><author>Bolea-Alamañac, Blanca ; Nutt, David J ; Adamou, Marios ; Asherson, Phillip ; Bazire, Stephen ; Coghill, David ; Heal, David ; Müller, Ulrich ; Nash, John ; Santosh, Paramala ; Sayal, Kapil ; Sonuga-Barke, Edmund ; Young, Susan J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c494t-4f10cc7e1cfb882fc5cf141ffa0370a925498a322e12b4ad1edbcec11813e7603</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adult</topic><topic>Attention Deficit Disorder with Hyperactivity - drug therapy</topic><topic>Attention Deficit Disorder with Hyperactivity - etiology</topic><topic>Attention Deficit Disorder with Hyperactivity - psychology</topic><topic>Attention deficit hyperactivity disorder</topic><topic>Biological and medical sciences</topic><topic>Central Nervous System Stimulants - therapeutic use</topic><topic>Child</topic><topic>Comorbidity</topic><topic>Consensus</topic><topic>Evidence-Based Medicine</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Mental health care</topic><topic>Nervous system (semeiology, syndromes)</topic><topic>Nervous system as a whole</topic><topic>Neurology</topic><topic>Neuropharmacology</topic><topic>Neuropsychology</topic><topic>Pharmacology. Drug treatments</topic><topic>Psychopharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bolea-Alamañac, Blanca</creatorcontrib><creatorcontrib>Nutt, David J</creatorcontrib><creatorcontrib>Adamou, Marios</creatorcontrib><creatorcontrib>Asherson, Phillip</creatorcontrib><creatorcontrib>Bazire, Stephen</creatorcontrib><creatorcontrib>Coghill, David</creatorcontrib><creatorcontrib>Heal, David</creatorcontrib><creatorcontrib>Müller, Ulrich</creatorcontrib><creatorcontrib>Nash, John</creatorcontrib><creatorcontrib>Santosh, Paramala</creatorcontrib><creatorcontrib>Sayal, Kapil</creatorcontrib><creatorcontrib>Sonuga-Barke, Edmund</creatorcontrib><creatorcontrib>Young, Susan J</creatorcontrib><creatorcontrib>British Association for Psychopharmacology</creatorcontrib><creatorcontrib>for the Consensus Group</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of Psychopharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bolea-Alamañac, Blanca</au><au>Nutt, David J</au><au>Adamou, Marios</au><au>Asherson, Phillip</au><au>Bazire, Stephen</au><au>Coghill, David</au><au>Heal, David</au><au>Müller, Ulrich</au><au>Nash, John</au><au>Santosh, Paramala</au><au>Sayal, Kapil</au><au>Sonuga-Barke, Edmund</au><au>Young, Susan J</au><aucorp>British Association for Psychopharmacology</aucorp><aucorp>for the Consensus Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: Update on recommendations from the British Association for Psychopharmacology</atitle><jtitle>Journal of Psychopharmacology</jtitle><addtitle>J Psychopharmacol</addtitle><date>2014-03-01</date><risdate>2014</risdate><volume>28</volume><issue>3</issue><spage>179</spage><epage>203</epage><pages>179-203</pages><issn>0269-8811</issn><eissn>1461-7285</eissn><coden>JOPSEQ</coden><abstract>Attention deficit hyperactivity disorder (ADHD) is a common condition with a high societal burden. The present guidelines summarise current literature, generating expert consensus recommendations for the treatment of ADHD in children and adults. These guidelines also provide a review of recent research in the fields of neuroimaging, neuropsychology and genetics of ADHD. Novel discoveries in these areas have informed physiological models for the disease. Since the publication of the previous British Association for Psychopharmacology guidelines in 2008, new drugs have been licensed and further compounds are being investigated. The publication of randomised controlled trials of psychological interventions has contributed to the range of treatment options for ADHD. As the disorder has been diagnosed more frequently there has been greater focus on comorbid conditions and how they impact treatment. Services have continued to develop for the treatment of ADHD in adults and care agreements have been introduced to facilitate access to treatment.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>24526134</pmid><doi>10.1177/0269881113519509</doi><tpages>25</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0269-8811 |
| ispartof | Journal of Psychopharmacology, 2014-03, Vol.28 (3), p.179-203 |
| issn | 0269-8811 1461-7285 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1516756086 |
| source | MEDLINE; SAGE Complete |
| subjects | Adult Attention Deficit Disorder with Hyperactivity - drug therapy Attention Deficit Disorder with Hyperactivity - etiology Attention Deficit Disorder with Hyperactivity - psychology Attention deficit hyperactivity disorder Biological and medical sciences Central Nervous System Stimulants - therapeutic use Child Comorbidity Consensus Evidence-Based Medicine Humans Medical sciences Mental health care Nervous system (semeiology, syndromes) Nervous system as a whole Neurology Neuropharmacology Neuropsychology Pharmacology. Drug treatments Psychopharmacology |
| title | Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: Update on recommendations from the British Association for Psychopharmacology |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T11%3A58%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evidence-based%20guidelines%20for%20the%20pharmacological%20management%20of%20attention%20deficit%20hyperactivity%20disorder:%20Update%20on%20recommendations%20from%20the%20British%20Association%20for%20Psychopharmacology&rft.jtitle=Journal%20of%20Psychopharmacology&rft.au=Bolea-Alama%C3%B1ac,%20Blanca&rft.aucorp=British%20Association%20for%20Psychopharmacology&rft.date=2014-03-01&rft.volume=28&rft.issue=3&rft.spage=179&rft.epage=203&rft.pages=179-203&rft.issn=0269-8811&rft.eissn=1461-7285&rft.coden=JOPSEQ&rft_id=info:doi/10.1177/0269881113519509&rft_dat=%3Cproquest_cross%3E3244085221%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1506565376&rft_id=info:pmid/24526134&rft_sage_id=10.1177_0269881113519509&rfr_iscdi=true |